PWPS
INKT icon

Pinnacle Wealth Planning Services’s MiNK Therapeutics INKT Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53 Hold
5
– – ﹤0.01% 2723
2025
Q4 		$56 Buy
+5
New +$65 ﹤0.01% 2738

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $139M AUM
AGWCA
Annis Gardner Whiting Capital Advisors Tampa, Florida $625M AUM 23.8% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Pinnacle Wealth Planning Services's INKT Position: Q1 2026 in Review

Pinnacle Wealth Planning Services held its MiNK Therapeutics (INKT) position steady in Q1 2026 at 5 shares worth $53. The position accounts for ﹤0.01% of the portfolio, ranked #2723.

Pinnacle Wealth Planning Services first reported a position in INKT in Q4 2025 and has held it in 2 quarters since. The position peaked at $56 in Q4 2025. 23 funds tracked by Wall St. Rank hold INKT as of Q1 2026.

  • Pinnacle Wealth Planning Services held 5 shares of MiNK Therapeutics worth $53 as of Q1 2026.
  • Pinnacle Wealth Planning Services left its MiNK Therapeutics share count unchanged in Q1 2026.
  • MiNK Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q1 2026, its #2723 holding.
  • Pinnacle Wealth Planning Services first reported a position in MiNK Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Pinnacle Wealth Planning Services's MiNK Therapeutics position peaked at $56 in Q4 2025.
  • 23 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2026, filed 11 May 2026.